JRCT ID: jRCT2031210130
Registered date:04/06/2021
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Basic Information
Recruitment status | Not Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Breast Cancer; HER2-positive; Metastatic |
Date of first enrollment | 23/08/2021 |
Target sample size | 1134 |
Countries of recruitment | Argentina,Japan,Canada,Japan,China,Japan,Denmark,Japan,Hungary,Japan,India,Japan,Italy,Japan,Korea,Japan,Peru,Japan,Philippines,Japan,Russian Federation,Japan,Saudi Arabia,Japan,Saudi Arabia,Japan,Spain,Japan,Sweden,Japan,Taiwan,Japan,Turkey,Japan,United Kingdom,Japan,United States,Japan |
Study type | Interventional |
Intervention(s) | Experimental: Arm A Trastuzumab deruxtecan (T-DXd) with pertuzumab-matching placebo Drug: Trastuzumab deruxtecan Administered by intravenous infusion Other Name: DS-8201a; T-DXd Drug: Placebo Administered by intravenous infusion Experimental: Arm B Trastuzumab deruxtecan (T-DXd) with pertuzumab Drug: Trastuzumab deruxtecan Administered by intravenous infusion Other Name: DS-8201a; T-DXd Drug: Pertuzumab Administered by intravenous infusion Active Comparator: Arm C Standard of care Drug: Taxane Investigator's choice of docetaxel or paclitaxel administered by intravenous infusion Drug: Pertuzumab Administered by intravenous infusion Drug: Trastuzumab Administered by intravenous infusion |
Outcome(s)
Primary Outcome | Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment |
---|---|
Secondary Outcome | 1.Progression Free Survival (PFS) by Investigator assessment 2.Overall Survival (OS) 3.Objective Response Rate (ORR) by BICR and Investigator assessment 4.Duration of Response (DoR) by BICR and Investigator Assessment 5.Time to second progression or death (PFS2) by Investigator assessment 6.Health related quality of life (HRQoL) using the EORTC QLQ-C30 7.Time to deterioration in EORTC-QLQ-C30 scores 8.Health related quality of life (HRQoL) using the EORTC QLQ-BR45 9.Serum concentration of trastuzumab deruxtecan and pertuzumab 10.Immunogenicity of trastuzumab deruxtecan, alone or with pertuzumab 11.Safety and tolerability of trastuzumab deruxtecan, alone or with pertuzumab |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | <= 130age old |
Gender | Both |
Include criteria | - Patients must be >=18 years of age(>=20 years of age - applicable for Japan only) - Pathologically documented breast cancer that: 1.is advanced or metastatic 2.is locally assessed and prospectively centrally confirmed as HER2-positive (IHC3+ or ISH+) 3.is documented by local testing as hormone receptor (HR)-positive or HR-negative disease in the metastatic setting - No prior chemotherapy or HER2-targeted therapy for advanced or metastatic breast cancer or only 1 previous line of endocrine therapy in the metastatic setting. Participants who have received chemotherapy or HER2-targeted therapy in the neo-adjuvant or adjuvant setting are eligible if > 6 months from treatment to metastatic diagnosis. - Has protocol-defined adequate organ and bone marrow function |
Exclude criteria | - Ineligible for any of the agents on the study. - Any substance abuse or other medical conditions that, in the investigator's opinion, may interfere with subject's participation or study results - Patients with spinal cord compression or clinically active central nervous system metastases. Participants with clinically inactive brain metastases or treated brain metastases that are no longer symptomatic may be included in the study. - Active or prior documented interstitial lung disease (ILD)/pneumonitis or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening - Prior randomization or treatment in a previous trastuzumab deruxtecan study regardless of treatment arm assignment |
Related Information
Primary Sponsor | Inoguchi Akihiro |
---|---|
Secondary Sponsor | AstraZeneca |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT04784715 |
Contact
Public contact | |
Name | Contact for Clinical Trial Information |
Address | 1-2-58, Hiromachi, Shinagawa-ku, Tokyo Tokyo Japan 140-8710 |
Telephone | +81-3-6225-1111 |
dsclinicaltrial@daiichisankyo.co.jp | |
Affiliation | DAIICHI SANKYO Co.,Ltd. |
Scientific contact | |
Name | Akihiro Inoguchi |
Address | 1-2-58, Hiromachi, Shinagawa-ku, Tokyo Tokyo Japan 140-8710 |
Telephone | +81-3-6225-1111 |
dsclinicaltrial@daiichisankyo.co.jp | |
Affiliation | DAIICHI SANKYO Co.,Ltd. |